In a 48-week phase 2 trial published in The New England Journal of Medicine , adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1]
The Canadian Competition Bureau has previously intervened in cases involving abuse of IP to block competition
Some doses are also available in vials
Evidence suggests it may promote weight loss by increasing calorie expenditure
(link: Study) Other studies show that GLP-1 doesnt generally cause tolerance in terms of long-term effectiveness
Confirm sample size, batch reference, seal, label, COA, chain of custody, storage condition and whether the sample comes from a commercial batch or development batch